Therefore, the anti-apoptotic and cardioprotective effects of ATOR indicated that it is a potentially useful agent for treating DCM, through its inhibition of the sustained activation of NF-κB signaling. Here, NFKB1 is linked to familial dilated cardiomyopathy.